Jean‐paul Sculier

Jean‐paul Sculier's AcademicInfluence.com Rankings

Jean‐paul Sculier

Medical

#2912

World Rank

#3356

Historical Rank

Oncology

#195

World Rank

#201

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Jean‐paul Sculier Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jean‐paul Sculier's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer (2016) (2632)
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) (2009) (718)
Towards tuberculosis elimination: an action framework for low-incidence countries (2015) (656)
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis (2004) (587)
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. (2001) (412)
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. (1995) (351)
The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer (2009) (327)
The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition (2008) (315)
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis (2002) (263)
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis (2001) (262)
A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. (1990) (247)
Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis (2004) (244)
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis (2002) (235)
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. (2000) (209)
Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. (2005) (203)
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. (2002) (191)
Prognostic factors for patients with small cell lung carcinoma (2000) (187)
Immune evasion before tumour invasion in early lung squamous carcinogenesis (2019) (172)
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis (2003) (170)
Health impacts of anthropogenic biomass burning in the developed world (2015) (159)
ESR/ERS white paper on lung cancer screening (2015) (152)
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. (1984) (150)
Evolution of microRNA expression during human bronchial squamous carcinogenesis (2008) (145)
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. (1994) (138)
Small-cell carcinoma of the lung: derivation of a prognostic staging system. (1991) (138)
Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. (1988) (137)
Nonsmall cell lung cancer (2013) (136)
A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. (1986) (135)
Chemotherapy of non-small-cell lung cancer. (1985) (135)
[The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer]. (2010) (134)
Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. (2006) (126)
Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. (1989) (125)
Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit (2000) (122)
The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. (2009) (118)
Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables (2011) (116)
Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. (1999) (114)
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature (2003) (112)
The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project (2009) (108)
Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients (2002) (104)
The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. (1998) (97)
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study (2010) (96)
Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience. (1990) (94)
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) (European Respiratory Journal (2009) 34 (17-41)) (2009) (93)
Endobronchial ultrasound and value of PET for prediction of pathological results of mediastinal hot spots in lung cancer patients. (2008) (90)
Neurologic disorders in patients with small cell lung cancer (1987) (90)
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. (1997) (86)
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. (1993) (84)
Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature (1991) (82)
Superior vena caval obstruction syndrome in small cell lung cancer (1986) (82)
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies (1997) (77)
Bevacizumab for non-small-cell lung cancer. (2007) (77)
Detection of bronchial preneoplastic lesions and early lung cancer with fluorescence bronchoscopy: a study about its ambulatory feasibility under local anaesthesis. (1999) (74)
Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. (1986) (72)
Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer (1990) (70)
[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. (2002) (70)
Endobronchial ultrasound and positron emission tomography positive mediastinal lymph nodes (2006) (70)
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. (1996) (68)
A prospective study of infections in lung cancer patients admitted to the hospital. (2003) (66)
Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. (1985) (65)
ESR/ERS white paper on lung cancer screening (2015) (62)
First- and second-line therapy for advanced nonsmall cell lung cancer (2009) (61)
Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. (1991) (59)
Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. (1984) (58)
Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification (2011) (58)
Idiopathic Small Airways Pathology in Patients with Graft-versus-Host Disease Following Allogeneic Bone Marrow Transplantation (1987) (58)
Synchronous roentgenographically occult lung carcinoma in patients with resectable primary lung cancer. (2000) (57)
Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. (2013) (57)
Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. (1987) (56)
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics (2001) (56)
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results (2006) (55)
Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma. (1990) (53)
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer (2000) (53)
An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. (2013) (52)
Is a specific oncological scoring system better at predicting the prognosis of cancer patients admitted for an acute medical complication in an intensive care unit than general gravity scores? (2004) (51)
Severe Pericardial Effusion in Patients with Concurrent Malignancy: A Retrospective Analysis of Prognostic Factors Influencing Survival (2008) (51)
Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. (1985) (50)
Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. (2002) (48)
Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor‐associated hypercalcemia: A randomized comparison between a 3‐day treatment and single 24‐hour infusions (1989) (47)
Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. (1994) (46)
Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. (2004) (46)
Progress in chemotherapy of non-small cell lung cancer. (1984) (44)
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. (2002) (43)
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations (2011) (43)
High-performance liquid chromatographic determination of amphotericin B in human serum. (1987) (43)
Citation indexes do not reflect methodological quality in lung cancer randomised trials. (2003) (42)
Superior vena cava obstruction syndrome: recommendations for management. (1985) (40)
The European initiative for quality management in lung cancer care (2014) (40)
Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience (2004) (39)
Lactic acidosis: a metabolic complication of extensive metastatic cancer. (1983) (37)
Iv administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man. (1983) (37)
Non-invasive ventilation for cancer patients with life-support techniques limitation (2006) (37)
A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. (1999) (37)
Medical cancer patients and intensive care. (1991) (36)
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC). (1996) (35)
Lung function evaluation before surgery in lung cancer patients: how are recent advances put into practice? A survey among members of the European Society of Thoracic Surgeons (ESTS) and of the Thoracic Oncology Section of the European Respiratory Society (ERS). (2009) (35)
COX-2 expression during early lung squamous cell carcinoma oncogenesis (2005) (35)
Synchronous lesions detected by autofluorescence bronchoscopy in patients with high-grade preinvasive lesions and occult invasive squamous cell carcinoma of the proximal airways. (2004) (35)
Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party. (1983) (35)
The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature (2001) (34)
Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer (1994) (34)
Prognostic factors in nonsmall cell lung cancer (2002) (33)
French Intensive Care Society, International congress – Réanimation 2016 (2016) (33)
Causes of deaths in an oncologic intensive care unit: a clinical and pathological study of 34 autopsies. (1990) (32)
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party. (1999) (32)
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. (2008) (31)
Noninvasive ventilation: application to the cancer patient admitted in the intensive care unit (2002) (30)
Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. (1994) (30)
Age and treatment of non-small-cell lung cancer: a database analysis in elderly patients. (2002) (30)
Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data (2015) (29)
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. (1998) (29)
Successful treatment of intractable hiccup with methylphenidate in a lung cancer patient (2003) (28)
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer (2000) (28)
A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. (2009) (27)
Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. (1989) (27)
Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe (2013) (27)
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. (2002) (26)
Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary study (2004) (26)
The lung cancer patient at the emergency department: a three-year retrospective study. (2013) (25)
Tumour stimulating effects of recombinant human interleukin-6 (1994) (25)
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. (2005) (25)
Chemotherapy improves low performance status lung cancer patients (2007) (24)
Expression of p53 in preneoplastic and early neoplastic bronchial lesions. (2002) (24)
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. (2004) (24)
Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. (1992) (24)
Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer. A randomized study. (1988) (24)
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. (2008) (23)
Leucopenia is an independent predictor in cancer patients requiring invasive mechanical ventilation: a prognostic factor analysis in a series of 168 patients (2003) (23)
Treatment of meningeal carcinomatosis. (1985) (23)
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. (2007) (23)
Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC? (2005) (23)
Electrocardiographic manifestations of heart metastasis from a primary lung cancer (2001) (22)
Epidemiology of infections in the adult medical intensive care unit of a cancer hospital (1997) (22)
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. (2002) (22)
Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. (1999) (22)
Monoclonal immunoradiometric assay and polyclonal radioimmunoassay compared for measuring neuron-specific enolase in patients with lung cancer. (1992) (22)
Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer (2005) (21)
Fluorescence bronchoscopy in high-risk patients: A comparison of LIFE and Pentax systems (2001) (21)
[Critical review of the randomized trials assessing the role of adjuvant thoracic irradiation and chemotherapy in the treatment of limited-stage small cell lung cancer]. (1998) (20)
A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer (1990) (20)
Cardiopulmonary resuscitation in medical cancer patients: the experience of a medical intensive-care unit of a cancer centre (1993) (19)
Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology (2016) (19)
A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party. (1990) (19)
Advances in target therapy in lung cancer (2015) (18)
Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. (1988) (18)
Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. (2006) (18)
Induction treatment for resectable non-small-cell lung cancer. (1997) (18)
Intensive care in the treatment of cancer patients. (1991) (18)
Assessment of the role of etoposide (VP16) and cisplatin (CDDP) in chemotherapy (CT) for small cell lung cancer (SCLC): a meta-analysis with a methodology assessment. (1999) (18)
Intensive chemotherapy in small cell lung cancer. (1986) (18)
Thoracic oncology in Europe: the ERS action plan by the Thoracic Oncology Assembly (2010) (17)
Multiple organ failure during interleukin-2 administration and LAK cells infusion (2004) (17)
Intraperitoneal chemotherapy with cisplatin and melphalan. (1988) (17)
Update in lung cancer and mesothelioma 2009. (2010) (17)
Best supportive care or chemotherapy for stage IV non-small cell lung cancer (1999) (17)
Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of Gram-negative bronchopneumonia. (1982) (17)
EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. (2008) (16)
Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer. (1990) (16)
Intensive care and oncology (1995) (15)
The role of thoracic radiation therapy in small cell carcinoma of the lung: a concensus report (1989) (15)
Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party. (1995) (15)
The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma (2008) (15)
Value of CEA determination in biological fluids and tissues. (1987) (15)
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. (2017) (15)
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. (2017) (14)
Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. (1998) (14)
Pharmacokinetics of Amphotericin B in Patients Receiving Repeated Intravenous High Doses of Amphotericin B Entrapped into Sonicated Liposomes (1989) (14)
Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium). (1986) (14)
Vibrio cholerae Bacteremia in a Neutropenic Patient with Non-Small-Cell Lung Carcinoma (2002) (13)
Role of intensive care unit in a medical oncology department. (1988) (13)
Consensus: the follow-up of the treated patient. (2003) (12)
What has the meta-analysis contributed to today's standard of care in the treatment of thoracic malignancies? (2008) (12)
Malignant Tumors of the Lung (2012) (12)
Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer. (1988) (12)
Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer. (1988) (12)
Phase I study of Amphotericin B lipid complex with ABLC pharmacokinetics in patients receiving antineoplastic therapy (1994) (12)
The European Respiratory Society plans its future: the 2013–2018 strategic plan (2014) (12)
Original article: A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer (1990) (11)
Dose-finding study of paclitaxel (Taxol1) plus cisplatin in patients with non-small cell lung cancer (1995) (11)
Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review (2019) (11)
Nonsurgical combined modality therapies in non-small cell lung cancer. (1986) (11)
Clinical phase I trial of marcellomycin with a single-dose schedule. (1983) (11)
Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]). (1991) (11)
Intensive care in anticancer centres: an international inquiry (1995) (11)
Cardiopulmonary resuscitation in cancer patients: indications and limits. (1995) (10)
Invasive mechanical ventilation in cancer patients: prior non-invasive ventilation is a poor prognostic factor (2010) (10)
A meta-analysis of the role of etoposide (VP16) and cisplatin (CDDP) in small cell lung cancer (SCLC) with a methodology assessment (1999) (10)
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party (2007) (10)
Original article: Intravenous administration of amphotericin B entrapped in liposomes: Induction of high serum levels of TNFα (1991) (10)
Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design (2014) (10)
A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. (2018) (10)
Pulmonologists and lung cancer: pivotal role in multidisciplinary approach (2013) (9)
Distribution in man of 111In-labelled liposomes containing a water-insoluble antimitotic agent. (1984) (9)
Splenic spontaneous rupture (SSR) and hemoperitoneum associated with low molecular weight heparin: a case report (2003) (9)
A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer (2017) (9)
Expression of thrombospondin in non-small cell lung cancer. (2002) (9)
[Endobronchial ultrasound and PET positive mediastinal lymph nodes]. (2006) (9)
Sepsis and Septic Shock Definitions in Patients With Cancer Admitted in ICU (2019) (9)
[Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease]. (1991) (9)
Rate and patterns of ICU admission among colorectal cancer patients: a single-center experience (2015) (9)
A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report. European Organization for the Research and Treatment of Cancer--Lung Cancer Working Party. (1990) (9)
Transient heart block. An unreported toxicity of high dose chemotherapy with cyclophosphamide and etoposide. (1985) (9)
Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study. (2008) (9)
Prognostic role of p53 in stage III non-small cell lung cancer. (2005) (9)
Angiogenesis in preinvasive, early invasive bronchial lesions and micropapillomatosis and correlation with EGFR expression (2007) (8)
Cisplatin or carboplatin for the treatment of non-small cell lung cancer: do they have equivalent efficacy? (2001) (8)
Medical anticancer treatment of lung cancer associated with comorbidities: a review. (2015) (8)
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions. (2017) (8)
Are Intensive Cares Worthwhile for Breast Cancer Patients: The Experience of an Oncological ICU (2016) (8)
EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions. (2006) (8)
Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party. (1994) (8)
A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer (1990) (8)
Biology of pulmonary preneoplastic lesions. (1997) (8)
In-vitro evaluation of the antifungal activity of amphotericin B entrapped into liposomes during storage for one year. (1990) (7)
European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small Cell Lung Cancer: III. Metastatic disease (2006) (7)
Updates in oncology (2014) (7)
HYPOTHERMIA AND HODGKIN’S DISEASE: CASE REPORT AND REVIEW OF THE LITERATURE (2006) (7)
Continuous Renal Replacement Therapy for Acute Renal Failure in Patients with Cancer: A Well-Tolerated Adjunct Treatment (2016) (7)
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. (2017) (7)
Staging of Lung Cancer (2009) (7)
Validation and comparison of several published prognostic systems for patients with small cell lung cancer (2011) (7)
A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC). (2006) (7)
Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha. (1991) (7)
An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC. (2013) (6)
Chemotherapy for malignant mesothelioma: a quantitative and qualitative overview of the literature (1999) (6)
ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe (2018) (6)
[Diagnostic. The new TNM classification for lung cancer]. (2008) (6)
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer (1994) (6)
Thoracic Oncology HERMES: a European syllabus towards a harmonised education and training of Thoracic Oncology specialists (2013) (6)
Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries (2018) (6)
[Meta-analysis: a guide to interpretation]. (2002) (6)
Diffuse bilateral pneumopathies in patients with cancer. (1987) (6)
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer. (1994) (5)
B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction. (2005) (5)
A preliminary evaluation of calcitonin and PDN-21 as tumor markers for lung cancer. EORTC Lung Cancer Working Party. (1989) (5)
La nouvelle classification TNM du cancer bronchique (2008) (5)
Non-invasive Ventilation in Cancer Patients: a historically matched controlled study (2006) (5)
Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working Party. (2012) (5)
[Febrile neutropenia at the emergency department of a cancer hospital]. (2011) (5)
[Indications and results of intensive care in patients with lung cancer]. (2007) (5)
[EGF-R expression correlation between biopsy and surgical specimens of lung carcinoma]. (2003) (5)
Thoracic malignancies, cisplatin and renal function (2011) (5)
OC-0062: An invidual data metaanalysis of phase II trials of adjuvant or induction chemotherapy for NSCLC treated with chemoRT (2014) (5)
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? (2015) (5)
Has Cox-2 a prognostic role in lung cancer ? A systematic review of the literature with meta-analysis of the survival results. (2005) (5)
Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party. (1995) (5)
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. 101473.1044@compuserve.com. (2000) (5)
Le patient atteint de cancer bronchique en réanimation (2014) (5)
The role of cisplatin in the treatment of small-cell lung cancer? (2001) (5)
Perspectives for the use of high-dose chemotherapy in the treatment of solid malignant tumors. (1984) (4)
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study (2015) (4)
[Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party]. (1997) (4)
Myelosuppression and infective complications (2001) (4)
Lung cancer diagnosis in the emergency department (2015) (4)
Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy (1999) (4)
Is there any usefulness for a specific scoring system in assessing the prognosis of cancer patients admitted to the intensive care unit? (2004) (4)
Lung cancer screening white paper: a slippery step forward? (2015) (4)
Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients (2008) (4)
161 Carboplatin prescribed in mg/m2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival and hematological toxicity? (1997) (4)
The role of HER-2/NEU expression on the survival of patients with non-small cell lung cancer (NSCLC): A systematic review of the literature with meta-analysis (2003) (4)
Traitements en oncologie thoracique : l’apport des méta-analyses (2005) (4)
Does c-erbB-2 play a role in the first steps of lung carcinogenesis? (2005) (4)
[Acute complications in lung cancer]. (2003) (4)
Pain control in thoracic oncology (2017) (4)
Proceedings of Réanimation 2017, the French Intensive Care Society International Congress (2017) (4)
Cisplatin-carboplatin-gemcitabine or ifosfamide-gemcitabine in advanced non-small cell lung carcinoma: two pilot studies. (1999) (4)
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes. (2017) (4)
CEA: A Useful Prognostic Marker in Small Cell Lung Cancer (1985) (4)
Citation factors are not reflecting the methodological quality of lung cancer randomised trials. (2002) (4)
[The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]. (2001) (3)
C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib. (2010) (3)
LE SYNDROME D'OBSTRUCTION DE LA VEINE CAVE SUPERIEURE (1982) (3)
[Conflicts of interest: a concept often (voluntary) ignored by physicians]. (2010) (3)
Intracardiac thrombosis associated with an acute consumption coagulopathy. (1987) (3)
Malignant tumors of the lung : evidence-based management (2004) (3)
Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent? (2007) (3)
[Management of resectable non-small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party]. (2014) (3)
A three-arm phase III randomised trial testing accelerated chemotherapy with GM-CSF or cotrimoxazole in extensive disease smal-cell lung cancer (2001) (3)
Intensive Multiple Drug Induction Chemotherapy for Small-Cell Lung Cancer (1990) (3)
High-dose chemotherapy of small-cell lung cancer with and without bone marrow transplantation. (1989) (3)
Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer (2005) (3)
ERS/ESTS Clinical guidelines on fitness for radical therapy in lung cancer patients (Surgery and chemo-radiotherapy) (vol 34, pg 17, 2009) (2009) (3)
Indications for intensive care in the management of infections in cancer patients. (1995) (3)
Combination chemotherapy with mitomycin C and vindesine in the treatment of non small cell lung carcinoma (NSCLC) (1985) (3)
Haematological colony-stimulating factor (CSF) in the treatment of small-cell lung cancer (SCLC): a systematic review of the literature with meta-analysis. (2001) (3)
Should maintenance chemotherapy be used to treat small cell lung cancer? (1998) (3)
The interdisciplinary treatment of pulmonary metastases. (1995) (3)
[Difficulties and limitations in conducting translational research in thoracic oncology. A practical example]. (2016) (3)
Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study. (2005) (3)
Accurate staging of radio-occult lung carcinomas may require multiple biopsies (2000) (3)
The role of angiogenesis, assessed by microvessel count (MVC), on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. (2002) (3)
Les recommandations de pratique clinique de l'European Lung Cancer Working Party: Mises à jour. (2014) (3)
Clinical features of lung cancer (2000) (3)
Late intensive chemotherapy with autologous bone marrow transplantation in small cell lung cancer: preliminary report of a pilot study (1984) (2)
Chemoradiotherapy for advanced non-small cell lung carcinoma (NSCLC) qualitative and quantitative evaluation of the literature. (1999) (2)
[The patient with lung cancer in intensive care]. (2014) (2)
A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancer. (1995) (2)
Histology as a Potential Clinical Predictor of Outcome in Advanced Non-Small-Cell Lung Cancer Treated with Vinorelbine and Mitomycin Combination Chemotherapy (2012) (2)
Which progress have the new agents brought for chemotherapy of advanced nonsmall cell lung cancer (2002) (2)
The European Lung Corner (2013) (2)
Metabolic Activation of 6-Nitrochrysene and 6-Aminochrysene in Vitro and in Vivo (1990) (2)
[Treatment of thoracic malignancy--results of meta-analyses]. (2005) (2)
[Anatomoclinical conference: breast cancer, hyperleukocytosis and respiratory failure]. (1997) (2)
A Pilot Study on a Muramyltripeptide Lipophilic Derivative Entrapped into Liposomes (CGP 19835A Lipid) in Patients with Advanced Non-Small-Cell Lung Cancer (1993) (2)
[Bad behaviors regarding research and scientific and medical publication]. (2013) (2)
Classification TNM du cancer bronchique (2014) (2)
The role of EGFR expression on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis (2001) (2)
General (Apache II –A- and SAPSII –S-) scoring systems and cancer specific scoring system for cancer patients admitted for an acute complication in a medical intensive care unit: short and long term prognosis (2001) (2)
A combination of 60 mg/m2 cisplatin (CDDP) and 200 mg/m2 carboplatin (CBDCA) is as active but less nephrotoxic than 120 mg/m2 CDDP in patients with advanced non-small cell lung cancer (NSCLC) (1993) (2)
Prognostic factor for patients with small cell lung cancer. (2000) (2)
O-002 Early lung carcinogenesis: MDM2 expression in bronchialpreneoplastic lesions and its correlation with p53 (2005) (2)
[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma]. (2018) (2)
Randomized trials evaluating radiotherapy adjuvant to chemotherapy for small cell lung carcinoma (SCLC): Qualitative evaluation before meta-analysis (1997) (2)
Causes of Death and Incidence of Life-support Techniques Limitations in Oncological Patients Dying in the ICU: A Retrospective Study (2013) (2)
Anticancer treatment for advanced non-small cell lung cancer (2011) (2)
Doit-on améliorer la classification TNM de 1997? (1999) (2)
Successful treatment with liposomal amphotericin B in two patients with persisting fungemia (1989) (2)
European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: IV. Limited disease. (2007) (2)
Radiotherapy combined with low-dose cisplatin; results of the EORTC 08844 phase III study by the EORTC Radiotherapy and Lung Cancer Cooperative Groups (1993) (2)
Evolution of biological pathways involved at successive steps of lung carcinogenesis. (2009) (2)
Complete remissions in non small cell lung cancer (1985) (2)
E05-05: IASLC staging project: prognostic factors (2007) (2)
[Diagnosis and treatment of early-stage bronchial cancer: current status]. (1997) (2)
A phase-ii study testing a combination chemotherapy with epirubicin and vindesine as 2nd line treatment for patients with advanced non-small-cell lung-cancer. (1995) (2)
Answer to comments on “Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.” by Berghmans T., et al. [Lung Cancer 49 (2005) 13–23] (2006) (2)
European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: I. Early stages (2006) (2)
A Pilot Study with an Ifosfamide, Carboplatin and Etoposide Regimen (ICE) in Patients with Advanced Non-Small-Cell Lung Cancer (1990) (2)
81 Maintenance chemotherapy in patients with small cell lung cancer after induction chemotherapy with ifosfamide, etoposide and anthracyclin: Randomized trial conducted by the european lung cancer working party (1995) (2)
A phase III randomized study comparing, in non-metastatic unresectable non-small cell lung cancer (NSCLC) responding to chemotherapy (CT), further CT to loco-regional irradiation (RT) (1998) (2)
Treatment with or without chemotherapy for locally advanced non-small cell lung cancer (NSCLC): a systematic review. (2000) (1)
WHO/ERS consultation : The role of e/mHealth in tuberculosis and tobacco control (2015) (1)
Prognostic role of thyroid transcription factor (TTF-1) in lung cancer: a meta-analysis of the published studies (2006) (1)
European Respiratory Society guideline on various aspects of quality in lung cancer care (2022) (1)
P-144 Epidermal growth factor receptor expression in preinvasive and early invasive bronchial lesions (2003) (1)
Role of p53 positivity on the survival of patients with lung cancer as assessed by a systematic review of the literature. (2000) (1)
Salvage with erlotinib plus bevacizumab: not in NSCLC (2011) (1)
Final results of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomized study by the European Lung Cancer Working Party. (2011) (1)
Spontaneous hyperuricemic acute renal failure. (1987) (1)
European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: V. Extensive diseases. (2007) (1)
TNM classification and clinicopathological factors: what is helpful for adjuvant chemotherapy decision after lung cancer resection? (2014) (1)
mTOR inhibitor sensitizes chemo-cytotoxicity for hepatocellular carcinoma (2006) (1)
[Positron emission tomography with 18F-FDG and cancer response to chemotherapy]. (2011) (1)
[Advances in the treatment of non-small cell lung cancer]. (1992) (1)
[A round table on the methodology of clinical trials. From the design to the meeting of the Oncology Group of the French-speaking members of the Society of Pneumology organized in Brussels 21 September 1990]. (1992) (1)
Etoposide (VP16) and Cisplatin (CDDP) merit their key role in chemotherapy (CT) for small cell lung cancer (SCLC): a meta-analysis with a methodology assessment (1999) (1)
A randomized trial comparing in small cell lung cancer (SCLC) induction chemotherapy by ifosfamide and etoposide with adriamycin (IVA) or epirubicine (IVE): An European lung cancer working party report (1993) (1)
[Superior vena cava obstruction syndrome]. (1982) (1)
Non-Invasive ventilation in cancer patients (2008) (1)
[The medical treatment of renal cancer in adults]. (1989) (1)
European Lung Cancer Working Party Clinical Practice Guidelines. Small Cell Lung Cnacer: IV. Limited disease (2007) (1)
[Uterine cervical carcinoma and pericardial effusion]. (2007) (1)
[Good and bad uses of the Impact Factor, a bibliometric tool]. (2004) (1)
O-214 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I — IIIa non-small cell lung cancer conducted by the European Lung Cancer working party (2003) (1)
Challenges and controversies in thoracic oncology: a new ERJ series (2014) (1)
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]. (1994) (1)
[Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non-small cell bronchial cancer]. (1995) (1)
[Maintenance chemotherapy in the treatment of small cell lung cancer: the advocate's view]. (1998) (1)
Multidisciplinary questions in thoracic oncology: the team experience (2016) (1)
[Thoracic oncology: annual review]. (2013) (1)
A prospective study of febrile neutropenia in lung cancer patients (2007) (1)
Gemcitabine combined with cisplatin and carboplatin (CCG) or ifosfamide (IG): a pilot study preparing a randomised phase III ELCWP study in stade IV non small-cell lung carcinoma (NSCLC) (1998) (1)
[Guidelines of clinical practice made by the European Lung Cancer Working Party: updates]. (2014) (1)
Abstract 1419: Characterization of the evolution of immune response in lung squamous carcinogenesis (2016) (1)
Smoking Control Is a Priority to Promote Heart, Lung, Blood, and Sleep Health. (2015) (1)
Long term survival after chemotherapy in patients with advanced unresectable non small cell lung cancer (NSCLC): A report by the European lung cancer working party (1993) (1)
[Lung cancer: Prognosis in intensive care depends mainly on the acute complication]. (2019) (1)
P-263 Is there a role of c-erbB-2 in the first steps of lung carcinogenesis? (2005) (1)
Gene expression differences in current versus former smokers lung squamous preneoplasia. (2010) (1)
[How can one insure the survival of clinical academic research?]. (2008) (1)
How much can patients, with low Karnofsky performance status and advanced non-small cell lung cancer, benefit from cisplatin-based chemotherapy? A retrospective analysis of a phase III randomised trial (2007) (1)
Role of Ki67 expression on survival of patients with lung cancer: a systematic review of the literature with meta-analysis (2004) (1)
[Cardiopulmonary resuscitation in cancer patients: experience of an intensive care unit in a cancer center]. (1996) (1)
Small cell lung cancer: what are the treatment results in routine management? (2014) (1)
[The Glasgow inflammatory score and lung cancer: A predictor of admissions to emergency units]. (2016) (1)
Rhinorrhea and Pseudomonas meningitis associated with a rhinopharyngeal tumor. (1982) (1)
Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data (2011) (1)
REANIMATION EN CANCEROLOGIE MEDICALE (1982) (1)
Evolution of miRNAs expression during lung squamous carcinogenesis. (2009) (1)
Prognostic factors for patients with small cell lung cancer: Analysis of a series of 763 patients with a minimal 5 years follow-up duration (2000) (1)
Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer. (1990) (1)
[Medical publications: real or false authors?]. (2009) (1)
Reflections on the current staging system for lung cancer (2002) (1)
Susceptibility of gram-negative bacteria isolated from the blood of cancer patients (1982) (1)
Critical factors for patient management. (2003) (1)
[Polychemotherapy of undifferentiated small cell bronchial cancer. Long-term results]. (1986) (1)
Aetiological diagnosis of acute respiratory failure in critical care oncology (2013) (1)
A59 Development of a software using a touch tone phone system and a vocal interface for automatic registration and randomization in multicenter clinical trials: Further experience of the European lung cancer working party (1993) (1)
Are Primary Tumour Standardized Uptake Value (PT SUVmax), Total lesion glycolysis (TLG) and metabolic volume (MV) measured on FDG PET(CT) predictors of survival in advanced Non-Small Cell Lung Cancer (NSCLC)? (2010) (0)
Efficacy of non-invasive ventilation in cancer patients (2005) (0)
A prospective infection survey in patients with lung cancer admitted to an oncological hospital (2001) (0)
A randomised phase III trial by the ELCWP comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based chemotherapy with the use of taxan as salvage treatment (2006) (0)
The second world conference on clinical co-operative research for lung cancer (2002) (0)
[Staging methods]. (2007) (0)
COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis. (2005) (0)
Value of EGFR, p53 and Ki-67 immunostaining in lung cancer biopsies (2002) (0)
[Adenopathy and eosinophilia]. (1999) (0)
MDM2 expression in bronchial preneoplastic lesions and its correlation with p53. (2005) (0)
A new treatment combining valproate acid (VA) plus doxorubicin (D) for patients with refractory or recurrent malignant mesothelioma (MM): a phase II study (2009) (0)
Correlation of p53, EGFR and Her-2 expression in the diagnostic biopsies and the corresponding resected tumours in NSCLC (2003) (0)
[Should we improve the TMN 1997 classification?]. (1999) (0)
Continuous venovenous haemofiltration (CVVHDF) in cancer patients with acute renal failure (ARF) is a safe and effective technique: Results of a retrospective study with multivariate analysis (2003) (0)
Daily low dose of cisplatin (P) radiochemotherapy for limited small cell lung cancer (SCCL): an European Lung Cancer Working Party phase III trial (2008) (0)
de l' European Lung Cancer Working Party : Mises à jour Guidelines of c linical practice made by the European Lung Cancer Working Party : Updates (2014) (0)
A phase III randomised trial testing accelerated chemotherapy with GM-CSF or cotrimoxazole in extensive-disease (ED) small-cell lung cancer (SCLS). A study by the European Lung Cancer Working Party (2001) (0)
16IN INCIDENTAL LUNG NODULES. WHAT DO YOU DO (2011) (0)
A phase III randomised trial testing accelerated chemotherapy with GM-CSF or cotrimoxazole in extensive-disease (ED) small-cell lung cancer (SCLC) (2001) (0)
A randomised trial comparing chemotherapy regimens with cisplatin (50 mg/m2) versus moderate doses of cisplatin and carboplatin in stage iv non-small cell lung cancer (2000) (0)
[The Third Annual Day of Thoracic Oncology of the Jules Bordet Institute, U.L.B]. (2002) (0)
Lung cancer: by B.E. Johnson and D.H. Johnson Wiley-Liss Inc, New York, USA (1996) (0)
Biology of bronchial precancerous lesions (2005) (0)
[Second meeting on severe emergencies and complications in cancer patients]. (2002) (0)
High-performance liquid chromatographic determination of 2-[3'-(methoxycarbonylamino)-phenyl]-3-phenyl-6-methoxycarbon ylamino-4-(3H)-quinazolone (NSC-251635) in human serum. (1985) (0)
A phase II study of cisplatin (CDDP) and epirubicin (EPI) in malignant pleural mesothelioma (MPM) (2003) (0)
[Ultrasound tracking of the progression of hepatic metastases treated by chemotherapy: a case of small cell carcinoma of the lung]. (1983) (0)
Factor 1 de transcripcion tiroidea - un nuevofactor pronostico en cancer de pulmon: un meta-analisis (2007) (0)
Intensive care and oncological emergencies (1999) (0)
Patients admitted with haematological malignancies in a cancer ICU (1999) (0)
[Cardiac arrest during TEP-scan]. (2009) (0)
The diagnosis and management of lung cancer in COPD (2002) (0)
Organization of a new medical intensive care unit (ICU): Nursing experience in a cancer institute (1993) (0)
Prophylactic cranial irradiation in SCLC: a systematic review of the literature (2000) (0)
Epidermal growth factor receptor expression in preneoplastic and early neoplastic bronchial lesions (2003) (0)
[Role of chemotherapy in the treatment of advanced stage non-small-cell bronchial cancer]. (1993) (0)
Implementation of clinical trials in unselected non-small cell lung cancer (NSCLC) patients: the mitomycin, ifosfamide, cisplatin (MIP) regimen (2005) (0)
Chemoradiotherapy for stage III unresectable non-small cell lung cancer (NSCLC) : a systematic review by the European Lung Cancer Working Party (ELCWP). (1999) (0)
P1.07-040 Prognostic Factors in Extensive Disease (ED) Small Cell Lung Cancer (SCLC): An ELCWP Phase III Randomized Trial: Topic: Prognostic Factors (2017) (0)
[Pemetrexed salvage chemotherapy for NSCLC: implementation study]. (2012) (0)
Gene expression differences in current and former smokers in lung squamous preneplasia. (2010) (0)
Identification of Microrna (MIRNA) Signatures for Response and Survival in Non-Small Cell Lung Cancer (NSCLC) Patients (PTS) Treated with Cisplatin-Vinorelbine (CV): A ELCWP Study (2012) (0)
A prospective infection survey in patients with lung cancer admitted to a cancer hospital (2001) (0)
A message from the ERS President and the ERS Secretary for EU Affairs (2015) (0)
[Chemotherapy in non-small cell bronchial carcinoma. 12 years' experience in an international cooperative group: EORTC Lung Cancer Working Party]. (1990) (0)
68 Neoadjuvant MIP (mitomycin C+ ifosfamide + cisplatin) chemotherapy for non metastatic unresectable non small cell lung cancer (NSCLC): Are there prognostic factors for response obtention after three courses? (1997) (0)
Early lung carcinogenesis: p14 expression in preneoplastic lesions and correlation with p53 and MDM2. (2006) (0)
Prior non invasive ventilation is a bad prognostic factor in mechanically ventilated cancer patients (2009) (0)
Immune evasion before tumour invasion in early lung squamous carcinogenesis (2019) (0)
An updated meta-analysis (MA) of the literature assessing the prognostic role of primary tumour standardized uptake value (SUV) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) in non-small cell lung cancer (NSCLC) (2009) (0)
European Lung Cancer Working Party Clinical Practice Guidelines Non-small Cell Lung Cancer: II. Unresectable Non-metastatic Stages (2006) (0)
[Role of an intensive care unit in a department of medical oncology (author's transl)]. (1982) (0)
Is chemosensitivity a predictive factor for radiosensitivity in non-small cell lung cancer? Lesson from European Lung Cancer working party phase III randomised trial (1998) (0)
Different gene expression profiles between current and former smokers in lung squamous carcinogenesis. (2010) (0)
[Central venous catheters with totally implanted injection ports: use and surveillance]. (1997) (0)
Abstract thirteenth annual meeting of the society for clinical trials May 10–13, 1992 Adam's Mark, Philadelphia, PennsylvaniaA software for registration and stratified randomization in multicenter clinical trials: The experience of the European lung cancer working party (1992) (0)
TRAITEMENT DU CANCER PULMONAIRE PAR UN GROUPE COOPERATEUR: EORTC LUNG CANCER WORKING PARY (BELGIQUE) (1983) (0)
[Future trends of liposomes in therapeutics]. (1983) (0)
[Hypothermia: a new approach to the treatment of cancer (author's transl)]. (1981) (0)
[Acute interstitial pneumonia and bronchial cancer]. (2002) (0)
[Anatomo-clinical conference: differential diagnosis of diffuse pneumopathies in bronchial cancer]. (1996) (0)
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial (2003) (0)
[Oncological intensive care: 2013 and 2014 years'review]. (2016) (0)
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) (2011) (0)
European School of Oncology First Euro-American Forum Treatment on Lung Cancer (2003) (0)
The expression of Ki-67 in preneoplastic and early neoplastic bronchial lesions (2002) (0)
[Immune responses in broncho-pulmonary cancer]. (2003) (0)
Intensive care for lung cancer patients (1999) (0)
Role of bcl-2 positivity on survival in patients with lung cancer: a meta-analysis with qualitative assessment of the literature (2000) (0)
Expression of p53 in lung preneoplastic and non-small cell lung cancer. (2000) (0)
Corticosteroids in sepsis and septic shock.: A Meta-analysis (1999) (0)
[The 13th Annual Thoracic Oncology Day]. (2012) (0)
A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study (2012) (0)
mRNA microarrays are able to predict outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V) : a ELCWP prospective study (2012) (0)
salvage treatment of advanced NSCLC after standard fi rst-line chemotherapy. (2011) (0)
The new wave of therapeutic chemical agents State of the art on lung carcinoma (1997) (0)
1083 Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma (NSCLC) treated by chemotherapy and radiotherapy (2003) (0)
Is the actual distinction among stage III NSCLC adequate enough?: A clinical assessment of a randomised trial before further biological investigations. (2003) (0)
Pain management in cancer patients (1983) (0)
Adjuvant therapy for limited non small cell lung cancer (NSCLC) patients: a literature review (1993) (0)
Correlation between genetic abnormalities of c-erbB-1 and c-erbB-2 receptors detected by fluorescence in situ hybridization (FISH) in lung cancer (2004) (0)
Haematological colony-stimulating factors (CSF) in febrile neutropenic patients: a systematic review of the literature with meta-analysis. (2001) (0)
Author reply (0)
[Pleural effusion]. (2020) (0)
Activated protein C in daily practice (2006) (0)
PROGRES RECENTS EN CHIMIOTHERAPIE DU CANCER BRONCHIQUE (1995) (0)
The role of cisplatine (CDDP) in association with etoposide (VP16) in chemotherapy for extensive small cell lung cancer (SCLC) (2002) (0)
[Richard Doll. A surprising story of conflicts of interest]. (2012) (0)
[Renal cysts - A novel complication of crizotinib treatment for lung cancer]. (2015) (0)
[Infectious risks and venous catheters in cancer patients]. (1985) (0)
1074 Evaluation of pre- and post-treatment serum levels of CYFRA 21–1 in lung cancer (LC) patients (PTS) (1995) (0)
The Belgian lung cancer working party (1986) (0)
Prognostic system in advanced NSCLC: A validation study by the ELCWP (2010) (0)
A literature-based qualitative and quantitative overview of chemotherapy versus best supportive care for stage IV non-small cell lung cancer (NSCLC) (1998) (0)
C7-02: Bronchial preneoplasia: MDm2 overexpression occurs before p14ARF and NPM aberrant expressions (2007) (0)
Lung cancer: Independent death predictor in cancer patients admitted after emergency visit (2016) (0)
Is it a place for mitomycin C (MMC) in the treatment of non-small cell lung cancer (NSCLC)? A meta-analysis (2000) (0)
[Fourteenth annual meeting of complications and emergencies of cancer patients]. (2014) (0)
O-264 A phase III randomized study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small cell lung cancer (NSCLC): a study by the European lung cancer working party (2003) (0)
Are biological variables adequate in better defining the staging system of stage III non small cell lung cancer (NSCLC)?: The example of the thyroid transcription factor 1 (TTF-1). (2006) (0)
[The 12th Annual Conference on Thoracic Oncology]. (2011) (0)
A phase III randomized study comparing concomitant standard cisplatin (P) etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small-cell lung cancer (SCLC) (2008) (0)
[Docetaxel as salvage treatment for non-small cell lung cancer: implementation study]. (2005) (0)
[Pregabaline (Lyrica) as a new medication for the treatment of peripheral neuropathic pain]. (2006) (0)
Is primary tumour standardizeds uptake volume (SUV) an independent prognostic factor for NSCLC (2011) (0)
[Thoracic Oncology 14th annual meeting]. (2013) (0)
[Mechanical ventilation in the cancer patient]. (2001) (0)
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party. (1994) (0)
Assayand PolyclonalRadioimmunoassay Compared for MeasuringNeuron-Specific Enolasein PatientswithLungCancer (1992) (0)
[Anatomo-clinical conference: bronchiolo-alveolar cancer and confusion]. (1997) (0)
[Treatment of lung cancer by a cooperative group: EORTC Lung Cancer Working Party (Belgium)]. (1983) (0)
Resectability after two different dose-intensity chemotherapy regimens: analysis of a randomised trial in initialy unresectable stage III non small cell lung cancer (2003) (0)
Prognostic factors in lung cancer: Is protocol inclusion in patients with lung cancer an independent prognostic factor? A retrospective study (2000) (0)
A phase III randomized study comparing weekly multiple drug chemotherapy versus standard combination for small cell lung cancer (1993) (0)
[The unit for administration and monitoring of intensive care at the Bordet Institute]. (1986) (0)
Qualitative evaluation, before meta-analysis, of the papers reporting on randomized trials testing the value of adjuvant radiotherapy to chemotherapy for small cell lung carcinoma (SCLC) (1997) (0)
[Implementation of an oncological care program in a multidisciplinary clinic]. (2016) (0)
Is the tolerance to MIP chemotherapy different between English and other European populations? (2005) (0)
Expression of MN-tumor associated antigen in resected non-small cell lung cancer (NSCLC): a new biomarker of in situ and invasive disease☆ (1998) (0)
[Cardiovascular toxicity of anticancer chemotherapy: 5 cases treated in intensive care]. (1995) (0)
[Contribution of mineralogical analysis in thoraciconcology: The example of asbestos. Answer from Morelle et al]. (2014) (0)
[The tenth conference on emergencies and severe complication in cancer patients]. (2010) (0)
Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function. (1990) (0)
Multimodality Treatment of Lung Cancer, Edited by Marcel Dekker, Inc, 2000 (2000) (0)
Oncological scoring system predicting prognosis (2004) (0)
[Prospects of new chemotherapies]. (1982) (0)
A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC) (2003) (0)
Nouvelle vague d'agents chimiotherapeutiques: Le point en cancerologie pulmonaire (1997) (0)
Induction chemotherapy by mitomycin C + ifosfamide + cisplatin (MTP) in patients with non metastatic unresectable non small cell lung cancer (NSCLC) (1993) (0)
P-143 Her-2/neu expression in lung cancer: comparison between immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) (2003) (0)
Non-invasive ventilation : new bricks in the wall (2005) (0)
The problem of performing adequately sized randomized trials to demonstrate small survival benefits. (2000) (0)
The expression of Ki-67, a marker of proliferative activity, in resected non-small cell lung cancer. (2001) (0)
The lung cancer patient in the emergency department: Causes of consultation and prognosis (2011) (0)
[Current therapeutic perspectives for precancerous pulmonary lesions: the retinoids]. (1985) (0)
A literature-based qualtative and quantitative overview of chemotherapy for malignant mesothelioma (1998) (0)
Oncologie thoracique : revue annuelle Thoracic oncology : annual review (2013) (0)
Occupational exposure to carcinogens and lung cancer: impact of a dedicated professional disease consultation in a Belgian oncologic centre (2011) (0)
[Oncological intensive care: 2011 year's review]. (2012) (0)
[Meta-analysis: a readers' guide]. (2004) (0)
Correlation between histological examination of bronchi from resected lung specimens and preoperative evaluation with fluorescence bronchoscopy (FB) (1999) (0)
Synchronous occult lung carcinoma (OLC) in patients with resectable primary lung cancer (1999) (0)
[12th meeting on emergency care and severe complications in the cancer patient]. (2011) (0)
Methodological evaluation, before quantitative review, of chemotherapy regimens for malignant mesothelioma (1999) (0)
[Recent experience using intensive chemotherapy with autologous bone marrow grafts in the treatment of solid tumors]. (1985) (0)
The 2nd Collaborative Symposium on General Thoracic Surgery ESTS-AATS-STS Postgraduate Course (2010) (0)
[Approach to the patient with bronchial cancer by the practicing physician]. (1986) (0)
[Adoptive immunotherapy with interleukin 2. Initial results of a pilot study in 6 cancer patients]. (1989) (0)
780 A phase II study of cisplatin (CDDP) and epirubicin (EPI) in malignant pleural mesothelloma (MPM). A study by the European Lung Cancer Working Party (ELCWP) (2003) (0)
AnOfficialAmericanThoracic Society / EuropeanRespiratory Society Statement : The Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer (2013) (0)
Selection of Antimicrobial Therapy in Septic Shock and Other Severe Infections (1987) (0)
A Phase I Study with an Ifosfamide, Carboplatin and Etoposide Regimen in Advanced Non-Small Cell Lung Cancer: An Interim Analysis (1989) (0)
Quality of life and supportive care (2008) (0)
Assessing response to chemotherapy in advanced non small cell lung cancer (NSCLC): morphological or metabolic criteria ? (2009) (0)
Unravelling the immune contexture of pre-invasive lesions of the lung by multispectral imaging (2018) (0)
Chemotherapy for Advanced Disease Non-Small Cell Lung Cancer (2004) (0)
[Current progress in chemotherapy for bronchial cancer]. (1995) (0)
Early diagnosis of lung cancer: historical background and perspectives (1998) (0)
A phase II trial assessing the activity of gemcitabine as second-line chemotherapy in non-small cell lung cancer (1999) (0)
[The 15th Eveline Markiewicz Meeting on emergencies and severe complications in cancer patients]. (2015) (0)
Combination Chemotherapy with Ifosfamide and Nimustine (IMA) as Salvage Treatment for Small Cell Lung Cancer (1993) (0)
204 speaker ROLE OF ADJUVANT CHEMOTHERAPY (2011) (0)
[Intensive chemotherapy treatment of small-cell bronchial cancer]. (1990) (0)
P-086 COX-2 expression during early lung squamous cell carcinomasoncogenesis (2005) (0)
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study (2015) (0)
The first World Conference on Clinical Cooperative Research for Lung Cancer, Brussels 4-6 March 1999. (1999) (0)
Evaluation of the role of EGFR as prognostic factor in stage III non small cell lung cancer (NSCLC): a retrospective analysis (2004) (0)
Classification TNM du cancer bronchique : ce qui pourrait changer en 2016 (2015) (0)
Are biological factors able to predict response to chemotherapy (CT) in advanced Non Small Cell Lung Cancer (NSCLC) ?: A feasibility study of tumour samplings (2011) (0)
Adjuvant therapy for non metastatic lung cancer patients: a methodological literature review (1993) (0)
P-082 Evaluation by immunohistochemistry of EGF-R expression beforeand after chemotherapy in non small cell lung cancer (2005) (0)
In memoriam: Eveline Markiewicz (2014) (0)
[Undifferentiated small cell bronchial cancer: role of the medical oncologist]. (1985) (0)
Evaluation by immunohistochemistry of EGF-R expression before and after chemotherapy in non small cell lung cancer (2005) (0)
[Let us avoid anti-evidence-based medicine]. (2008) (0)
[A rare cause of superior vena cava syndrome]. (2011) (0)
1282 International inquiry about intensive care in anticancer centers (1995) (0)
Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis (2013) (0)
91 Delivered dose intensity with an induction chemotherapy (CT) by ifosfamide, etoposide and anthracyclin for patients (PTS) with small cell lung cancer (SCLC): A report by the european lung cancer working party (1995) (0)
Palliative Noninvasive Mechanical Ventilation in Patients with Hematological Malignancies (2011) (0)
Adjuvant therapy for limited small cell lung cancer (SCLC) patients: a methodological literature review (1993) (0)
[Anatomo-clinical conference: pulmonary cancer and cerebral vascular accident]. (1998) (0)
Treatment of lung cancer 3262 Bevacizumab ( Avastin ® ) aerosol therapy ( AT ) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer ( NSCLC ) (2012) (0)
A phase I study of gemcitabine combined with cisplatin and carboplatin (CCG) or ifosfamide (IG) in stade IV non small cell lung cancer. (1998) (0)
[Liposomes and infection. Therapeutic possibilities and current clinical findings]. (1988) (0)
Docetaxel plus cisplatin or carboplatin is as effective, but may be safer and more practical than vinorelbine plus cisplatin for treating non-small cell lung cancer (2002) (0)
Prophylactic cerebral irradiation in small cell lung cancer: a systematic review of the literature with meta-analyses (2002) (0)
Pharmaco-economic evaluation of 2 induction regimens prior to surgery for NSCLC (2008) (0)
The role of mitomycin C (MMC) in the treatment of non-small cell lung cancer (NSCLC):a meta-analysis of the literature (2000) (0)
Prophylactic cranial irradiation in SCLC: a systematic review of the literature with meta-analysis (2002) (0)
[Stage IV non-small cell lung cancer. What is the best treatment for relapse?]. (2006) (0)
Misdiagnosed Brugada syndrome discovered during lung cancer chemotherapy (2001) (0)
[The 11th Meeting on emergencies and severe complications in cancer patients ]. (2010) (0)
A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics (2001) (0)
145PD PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS (PTS) WITH SMALL CELL LUNG CANCER (SCLC): VALIDATION STUDY OF A PUBLISHED CLASSIFICATION (2009) (0)
[Adoptive immunotherapy: a new therapeutic approach to cancer based on interleukin 2]. (1987) (0)
Fluorescence bronchoscopy in the early detection of occult carcinoma and carcinoma in situ (2001) (0)
[What are the questions concerning small cell lung cancer? How should research be orientated?]. (2004) (0)
[Anatomo-clinical conference: bronchial cancer and massive hemoptysis]. (1996) (0)
6 A phase III randomized trial evaluating in patients with advamced non small cell lung cancer (NSCLC) the addition of ifosfamide to a combination of cisplatin and carboplatin (1997) (0)
A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and /or gemcitabine in stage IV non-small cell lung cancer (NSCLC): an european lung cancer working party study (2001) (0)
Infections in patients with lung cancer (2000) (0)
Muldisciplinary conference (MDC), oncological program (OP) and practice guidelines (GL): The experience of the lung cancer (LC) clinic of a cancer hospital (2014) (0)
Molecular profiling of lung squamous carcinogenesis (2013) (0)
[Respiratory distress and its treatment in the cancer patient]. (1990) (0)
[Online guide as a frame in clinical teaching of disease: an example at www.oncorea.com]. (2008) (0)
[Oncological intensive care: review of 2012 literature]. (2014) (0)
A randomised trial comparing chemotherapy regimens with cisplatin (50mg/m2) versus moderate doses of cisplatin and carboplatin in stage IV non-small cell lung cancer (1999) (0)
Characteristics of occult carcinomas of the lung (OCL): experience of light induced fluorescence bronchoscopy (LIFE) (1998) (0)
Continuous venovenous haemofiltration (CVVHDF) in cancer patients with acute renal failure (ARF): Results of a retrospective study with multivariate analysis. (2004) (0)
Evolution of genomic profile during successive steps of lung squamous carcinogenesis. (2009) (0)
67O ARE FIRST-LINE PLATINUM-BASED (PT) REGIMENS IMPROVING SURVIVAL IN COMPARISON WITH NON-PLATINUM (NPT) CHEMOTHERAPY (CT) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)? A META-ANALYSIS (MA) OF RANDOMISED TRIALS (2013) (0)
[Anatomical-clinical conference: mediastinal mass]. (1999) (0)
Validation and comparison of published prognostic classification for survival in patients (pts) with small cell lung cancer (SCLC). (2010) (0)
[The role of prophylactic cranial irradiation in small cell lung cancer]. (2021) (0)
[Image of the month. Pulmonary mass and smoking]. (2001) (0)
A phase III randomised study comparing standard cisplatin (P)- etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small cell lung cancer (SCLC) (2008) (0)
Mitomycin C (MMC) in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis with qualitative assessment. (2000) (0)
Mechanical ventilation in a medical cancer patients population (1999) (0)
[Intensive chemotherapy with bone marrow autograft in solid tumors]. (1983) (0)
Nouvelle classification TNM (2011) (0)
Identification of a microRNA (miRNA) based signature for survival in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with cisplatin-vinorelbine: A ELCWP study. (2012) (0)
American Thoracic Society Documents An Ofﬁcial American Thoracic Society/European Respiratory Society Statement: The Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer (2013) (0)
Is there a need for prophylactic cranial irradiation in small-cell lung cancer? No: Current topics (2001) (0)
25IN SMALL CELL LUNG CANCER (2009) (0)
Salvage chemotherapy with pemetrexed (PEM) for non small cell lung cancer (NSCLC): an implementation study (2010) (0)
Non-invasive ventilation: application to the cancer patient (2002) (0)
c-erbB1 and c-erbB-2 receptors genetic abnormalities and protein expression in lung cancer (2004) (0)
Studies on lung cancer management in routine practice. (2013) (0)
Activity of drugs recently introduced in the market for the treatment of non-small cell lung cancer (1998) (0)
A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC) (2016) (0)
[Treatment of bronchial non-small cell cancer: point of view of the cancer internist]. (1984) (0)
A phase III randomized study comparing two different dose-intensity regimens as neoadjuvant chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small cell lung cancer (2003) (0)
Second-line paclitaxel for primary or secondary failure in non-small cell lung cancer (NSCLC) initially treated with cisplatin-gemcitabine-ifosfamide (GIP) A preliminary analysis of a study by the ELCWP (2006) (0)
[Clinical pathological consultation: lung mass]. (1998) (0)
Comparison of two chemotherapy regimens, in stage IV non small cell lung cancer (NSCLC), based on cisplatin or on the combination of cisplatin and carboplatin: a randomized trial conducted by the European Lung Cancer Working Party (2000) (0)
Concurrent radiochemotherapy (RT-CT) with cisplatin (C), gemcitabine (G) and vinorelbine (V) in patients with locally advanced non-small cell lung cancer (NSCLC): preliminary toxicity results within a randomized trial of European Lung Cancer Working Party (ELCWP) (2004) (0)
A comparison between 2 techniques (immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH)) for Her-2/neu detection in lung cancer (2003) (0)
Spontaneous hyperuricemic acute renal failure on oncologic emergency (1987) (0)
Admitting lung cancer patients to intensive care for organ dysfunction: a complex decision process (2015) (0)
[Mediastinal mass, pulmonary infiltration, and meningitis]. (2002) (0)
881 Safety and tolerance of lung imaging fluorescence endoscopy (LIFE) under local anesthesia (1997) (0)
Chemotherapy for advanced non-small cell lung cancer (2004) (0)
Concomitant chemoradiotherapy (CTRT) as induction versus consolidation treatment in patients (pts) with stage III unresectable non-small cell lung cancer (NSCLC): a phase III randomized study by the European Lung Cancer Working Party. (2008) (0)
Initiation of a new anti-cancer medical treatment in ICU: a retrospective study (2021) (0)
[New wave of chemotherapeutic agents: update in pulmonary oncology]. (1997) (0)
A proposal in small cell lung cancer staging according to TNM system (2012) (0)
[The treatment with prostaglandin E1 of a suspected hepatic veno-occlusive disease in a leukemic patient]. (1988) (0)
[Impact of routine brain imaging in the initial management of lung cancer]. (2018) (0)
[13th meeting on cancer-related emergencies and cancer-related severe complications]. (2012) (0)
Evolution of gene expression profiling at successive steps of lung squamous carcinogenesis. (2009) (0)
[Seventh annual meeting of thoracic oncology]. (2006) (0)
Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): a feasibility study on tissue collection (2010) (0)
[15th annual workshop of thoracic oncology (JAOT)]. (2014) (0)
880 Proposal of a more discriminant TNM stage grouping in patients with clinical stage III non small cell lung cancer (NSCLC) treated by primary chemotherapy (1997) (0)
Cisplatin (CDDP), etoposide (VP16) and vindesine (VDA) in non small cell bronchogenic carcinoma (NSCBC) (1982) (0)
[Non-small-cell bronchial cancers at stage III. Therapeutic strategy]. (1998) (0)
[Late intensive chemotherapy with bone marrow autograft. Pilot study in small cell bronchial cancer]. (1983) (0)
Prognostic factors for survival in patients with small cell lung cancer: validation study of a published classification (2009) (0)
Survival and long term survival analysis in advanced non small cell lung cancer (NSCLC): The experience of the European lung cancer working party (1993) (0)
Diffusion-Weighted Imaging: Superior to FDG-PET at Identifying Pulmonary Malignancy? (2015) (0)
Characteristics and management of occult carcinomas of the lung: experience of autofluorescence bronchoscopy (1997) (0)
[Oncology congress on emergencies and severe cancer complications]. (2001) (0)
Which progress have the new agents brought for chemotherapy of advanced NSCLC (2001) (0)
Lung cancer diagnosis in the emergency (2015) (0)
Overexpression of vascular endothelial growth factor (VEGF) and receptor in micropapillomatosis, a preneoplastic bronchial lesion ☆ (1998) (0)
Monoclonal ImmunoradiometricAssay and Polyclonal Radioimmunoassay Compared for Measuring Neuron-Specific Enolase in Patients with Lung Cancer (2004) (0)
[Detection of early stage bronchopulmonary cancer: contribution of bronchoscopy]. (2003) (0)
[Current topics in pulmonary oncology]. (1997) (0)
[Therapeutic results in the treatment of small cell bronchial cancer: experience of the EORTC Lung Cancer Working Party (Belgium)]. (1987) (0)
Parameters of the immune reaction as prognostic factors in lung cancer (1993) (0)
[Anatomo-clinical conference: lymphoma and mediastinal mass]. (1997) (0)
Classi cation TNM du cancer bronchique TNM classi cation for the lung cancer (2014) (0)
[Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy]. (1997) (0)
Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries (2018) (0)
[Our Society's handling of the mad cow crisis and smoking: where is good sense?]. (2001) (0)
Educational approach of critical care nurses having to manage medical anticancer treatment in clinical trials (1993) (0)
P-194 A feasibility study preparing to a phase III randomised trialcomparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. A trial conducted by the European Lung Cancer Working Party (ELCWP) (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jean‐paul Sculier?

Jean‐paul Sculier is affiliated with the following schools:

Université libre de Bruxelles

Jean‐paul Sculier's Academic­Influence.com Rankings

Why Is Jean‐paul Sculier Influential?

Jean‐paul Sculier's Published Works

Published Works

What Schools Are Affiliated With Jean‐paul Sculier?

Jean‐paul Sculier's AcademicInfluence.com Rankings